Genmab A/S (GNMSF) News Today $221.78 -1.32 (-0.59%) As of 02/21/2025 02:09 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Genmab A/S (OTCMKTS:GNMSF) Sees Large Drop in Short InterestGenmab A/S (OTCMKTS:GNMSF - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 80,900 shares, a decrease of 20.5% from the January 15th total of 101,800 shares. Based on an average daily volume of 21,300 shares, the days-to-cover ratio is presently 3.8 days.February 16, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Releases Earnings Results, Beats Estimates By $5.24 EPSGenmab A/S (OTCMKTS:GNMSF - Get Free Report) announced its earnings results on Wednesday. The company reported $5.70 earnings per share for the quarter, beating the consensus estimate of $0.46 by $5.24. Genmab A/S had a net margin of 23.49% and a return on equity of 17.73%.February 15, 2025 | marketbeat.comGenmab A/S Announces Annual General MeetingFebruary 13, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?Genmab A/S (OTCMKTS:GNMSF) Stock Crosses Below 200 Day Moving Average - Here's What HappenedFebruary 13, 2025 | marketbeat.comQ4 2024 Genmab A/S Earnings Call TranscriptFebruary 13, 2025 | gurufocus.comGenmab A/S (OTCMKTS:GNMSF) Reaches New 12-Month Low - What's Next?Genmab A/S (OTCMKTS:GNMSF) Reaches New 12-Month Low - Time to Sell?February 10, 2025 | marketbeat.comMorgan Stanley Keeps Their Hold Rating on Genmab (GMAB)February 10, 2025 | markets.businessinsider.comWhy Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to AnalystsFebruary 8, 2025 | msn.comGenmab A/S (GNMSF) Projected to Post Earnings on WednesdayGenmab A/S (OTCMKTS:GNMSF) will be releasing earnings on Wednesday, February 12, Financial Modeling Prep reports.February 5, 2025 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Hits New 1-Year Low - Here's WhyGenmab A/S (OTCMKTS:GNMSF) Sets New 1-Year Low - Here's What HappenedFebruary 3, 2025 | marketbeat.comGenmab Expands Financial Flexibility with Increased Share Capital and WarrantsJanuary 29, 2025 | tipranks.comGenmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week Low - Time to Sell?Genmab A/S (OTCMKTS:GNMSF) Sets New 1-Year Low - Time to Sell?January 28, 2025 | marketbeat.comGenmab's SWOT analysis: biotech firm's stock faces growth and integration challengesJanuary 24, 2025 | msn.comGenmab A/S (OTCMKTS:GNMSF) Share Price Passes Above 50-Day Moving Average - Here's WhyGenmab A/S (OTCMKTS:GNMSF) Stock Passes Above Fifty Day Moving Average - Should You Sell?January 24, 2025 | marketbeat.comStrong Sales and Robust Pipeline Reinforce Genmab’s Buy RatingJanuary 23, 2025 | markets.businessinsider.comIs Genmab (GMAB) the High Growth International Stock to Invest in Now?January 23, 2025 | insidermonkey.comGenmab (GMAB) Gets a Hold from Morgan StanleyJanuary 13, 2025 | markets.businessinsider.comGenmab A/S (0MGB) Receives a Buy from UBSJanuary 13, 2025 | markets.businessinsider.comBarclays Sticks to Its Buy Rating for Genmab A/S (0MGB)January 10, 2025 | markets.businessinsider.comGenmab Receives Buy Rating on Promising Pipeline and Strategic DevelopmentsJanuary 8, 2025 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Short Interest UpdateGenmab A/S (OTCMKTS:GNMSF - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 119,300 shares, an increase of 9.4% from the November 30th total of 109,000 shares. Based on an average daily trading volume, of 4,500 shares, the days-to-cover ratio is currently 26.5 days.December 31, 2024 | marketbeat.comTD Cowen Reaffirms Their Hold Rating on Genmab (GMAB)December 13, 2024 | markets.businessinsider.comGenmab A/S: Circling Back On This Complicated StoryDecember 13, 2024 | seekingalpha.comGenmab A/S Expands Share Capital and WarrantsDecember 4, 2024 | tipranks.comGenmab Discloses Share Transactions by ExecutivesDecember 3, 2024 | tipranks.comWhy Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now?December 2, 2024 | msn.comGenmab A/S Plans Strategic Capital Expansion by 2029November 27, 2024 | tipranks.comJefferies Sticks to Their Hold Rating for Genmab A/S (0MGB)November 27, 2024 | markets.businessinsider.comGenmab to Present at Citi’s Global Healthcare ConferenceNovember 25, 2024 | uk.finance.yahoo.comBarclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)November 19, 2024 | markets.businessinsider.comShort Interest in Genmab A/S (OTCMKTS:GNMSF) Decreases By 10.1%Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 76,300 shares, a drop of 10.1% from the October 15th total of 84,900 shares. Based on an average daily trading volume, of 16,400 shares, the short-interest ratio is currently 4.7 days.November 18, 2024 | marketbeat.comGenmab price target lowered to DKK 2,250 from DKK 2,500 at Deutsche BankNovember 14, 2024 | markets.businessinsider.comTruist Financial Sticks to Its Buy Rating for Genmab (GMAB)November 8, 2024 | markets.businessinsider.comGenmab’s Mixed Earnings and Strategic Developments Lead to Hold RatingNovember 8, 2024 | markets.businessinsider.comGenmab Reports Strong Growth and Strategic AdvancesNovember 7, 2024 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Stock Crosses Below 200 Day Moving Average - Here's What HappenedGenmab A/S (OTCMKTS:GNMSF) Stock Passes Below 200-Day Moving Average - Should You Sell?October 31, 2024 | marketbeat.comGenmab A/S (OTCMKTS:GNMSF) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?October 23, 2024 | marketbeat.comGenmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for Third Quarter of 2024October 17, 2024 | finanznachrichten.deGenmab A/S (GMAB): Leading Innovation in Antibody TherapeuticsOctober 17, 2024 | msn.comUBS Keeps Their Buy Rating on Genmab A/S (0MGB)October 16, 2024 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Hits New 52-Week Low - Time to Sell?Genmab A/S (OTCMKTS:GNMSF) Reaches New 52-Week Low - Here's What HappenedOctober 15, 2024 | marketbeat.comMorgan Stanley Reaffirms Their Hold Rating on Genmab (GMAB)October 15, 2024 | markets.businessinsider.comGenmab A/S (0MGB) Receives a Buy from BarclaysOctober 11, 2024 | markets.businessinsider.comGenmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge FundsOctober 9, 2024 | insidermonkey.comInvestigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1 ...September 16, 2024 | businesswire.comGenmab A/S (OTCMKTS:GNMSF) Share Price Passes Below 200-Day Moving Average of $278.03Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Below 200-Day Moving Average of $278.03September 12, 2024 | marketbeat.comUBS Sticks to Their Buy Rating for Genmab A/S (0MGB)September 11, 2024 | markets.businessinsider.comGenmab A/S (OTCMKTS:GNMSF) Stock Passes Above Fifty Day Moving Average of $264.64Genmab A/S (OTCMKTS:GNMSF) Stock Price Passes Above 50-Day Moving Average of $264.64September 4, 2024 | marketbeat.comStrong Pipeline and Regulatory Approval Prospects Affirm Buy Rating for GenmabAugust 27, 2024 | markets.businessinsider.comGenmab A/S (NASDAQ:GMAB) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | msn.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address GNMSF Media Mentions By Week GNMSF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNMSF News Sentiment▼1.280.61▲Average Medical News Sentiment GNMSF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNMSF Articles This Week▼11▲GNMSF Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Daiichi Sankyo News Today Takeda Pharmaceutical News Today argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Summit Therapeutics News Today Intra-Cellular Therapies News Today Viatris News Today Genmab A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:GNMSF) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
